

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4171684

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
QINGHUA WANG	01/15/2015
RECEIVING PARTY DATA	
Name:	HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO. LTD.
Street Address:	14 SCIENCE MUSEUM ROAD
Internal Address:	UNIT 17, 9/F, TOWER A
City:	HONG KONG
State/Country:	CHINA
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8658174
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2134261771
Email:	stevenreiss@scienbizippc.com
Correspondent Name:	STEVE REISS
Address Line 1:	550 SOUTH HOPE STREET
Address Line 2:	SUITE 2825
Address Line 4:	LOS ANGELES, CALIFORNIA 90071
NAME OF SUBMITTER:	STEVE REISS
SIGNATURE:	/steve reiss/
DATE SIGNED:	12/06/2016
Total Attachments: 1	
source=Assignment US Patent 8658174#page1.tif	

PATENT ASSIGNMENT

THIS AGREEMENT, to be effective as of January 15, 2015, is by and between assignor, **QINGHUA WANG**, having a residence at 22 Bond Ave. Toronto, Ontario M3B 3R8, Canada, and assignee, **HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.**, having its principal place of business at Unit 17, 9/F., Tower A, New Mandarin Plaza, No.14 Science Museum Road, Tsimshatsui, Kowloon, Hong Kong.

WITNESSETH:

WHEREAS, **QINGHUA WANG** is the owner of a 100% interest in and to U.S. Patent No. 8,658,174, issued on February 25, 2014, filed on October 15, 2008 with Application No. 11/996,776, entitled GLP/1/EXENDIN 4 IGG FC FUSION CONSTRUCTS FOR TREATMENT OF DIABETES (hereinafter "the Patent Rights"); and

WHEREAS, **HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.** desires to obtain, and **QINGHUA WANG** is willing to assign his 100% interest in the Patent Rights to **HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.**;


NOW, THEREFORE, for good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the parties hereby agree as follows:


QINGHUA WANG does hereby sell, assign, transfer, and set over unto **HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.** 100% of his right, title, and interest in, to, and under (i) U.S. Patent No. 8,658,174, issued on February 25, 2014, (ii) all patents which may issue from such patent or application including any continuations, divisionals, and continuations-in-part thereof, and (iii) the inventions claimed in such patents and application.

IN WITNESS WHEREOF, **QINGHUA WANG** and **HONG KONG INNOGEN PHARMACEUTICAL TECHNOLOGY CO., LTD.** have each caused their duly authorized representative to execute this Assignment.

QINGHUA WANG

**HONG KONG INNOGEN
PHARMACEUTICAL
TECHNOLOGY CO., LTD.**

Signature: 

Signature: 

Print Name: QINGHUA WANG

Print Name: XIANG GAO

Title: _____

Title: Director and CEO

Date: January 15, 2015

Date: January 15, 2015

for and on behalf of
Hong Kong InnoGen Pharmaceutical Technology Co., Limited
香港英諾醫藥技術有限公司